药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Mecasermin
Solanezumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Solanezumab.
Mecasermin
Onartuzumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Onartuzumab.
Mecasermin
Depatuxizumab mafodotin
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Depatuxizumab mafodotin.
Mecasermin
Bapineuzumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Bapineuzumab.
Mecasermin
Durvalumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Durvalumab.
Mecasermin
Figitumumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Figitumumab.
Mecasermin
Ficlatuzumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Ficlatuzumab.
Mecasermin
Tabalumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Tabalumab.
Mecasermin
Conatumumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Conatumumab.
Mecasermin
Human Varicella-Zoster Immune Globulin
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Human Varicella-Zoster Immune Globulin.
Mecasermin
Eftrenonacog alfa
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Eftrenonacog alfa.
Mecasermin
Tetanus Immune Globulin
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Tetanus Immune Globulin.
Mecasermin
Atezolizumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Atezolizumab.
Mecasermin
Necitumumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Necitumumab.
Mecasermin
Daratumumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Daratumumab.
Mecasermin
Evolocumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Evolocumab.
Mecasermin
Alirocumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Alirocumab.
Mecasermin
Idarucizumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Idarucizumab.
Mecasermin
Asfotase alfa
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Asfotase alfa.
Mecasermin
Dulaglutide
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Dulaglutide.